FiercePharma

RELVAR™ ELLIPTA™ gains approval in Japan for the treatment of asthma

GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved RELVAR™ ELLIPTA™ for the treatment ...
FiercePharma

GSK and Theravance announce positive data from two studies evaluating the efficacy and safety of Incruse™ Ellipta® when added to Relvar®/Breo® Ellipta® in patients with COPD

Relvar Ellipta is not indicated for the treatment of COPD in Japan. Relvar Ellipta is approved in Europe for the symptomatic treatment of adults with chronic obstructive pulmonary disease (COPD) with ...
PharmaTimes

EMA advisors back GSK/Theravance lung combo Relvar

The EMA’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorisation for Relvar Ellipta, a combination of the inhaled corticosteroid fluticasone ...
London South East

RELVAR ELLIPTA Receives Approval in Japan

LONDON, UK, 20 September, 2013 - Skyepharma PLC (LSE: SKP), the expert oral and inhalation drug delivery company, announces that the regulatory committee (Bunka-Kai) of the Japanese Ministry of Health ...